Financial reports
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
10 Aug 21
Current reports
8-K
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
25 Mar 24
8-K
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
21 Mar 24
8-K/A
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
6 Mar 24
8-K
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
29 Feb 24
8-K
FDA Issues Reminder of Non-Substitution of PEDMARKÒ (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
2 Feb 24
8-K
Fennec Announces Incremental $5 Million Investment from Petrichor
5 Dec 23
8-K
Fennec Pharmaceuticals Announces Third Quarter 2023
6 Nov 23
8-K/A
Fennec Pharmaceuticals Announces Second Quarter 2023
7 Aug 23
8-K
Fennec Pharmaceuticals Announces Second Quarter 2023
4 Aug 23
8-K
Fennec Pharmaceuticals Announces Second Quarter 2023
4 Aug 23
Registration and prospectus
424B7
Prospectus with selling stockholder info
15 Mar 24
S-3
Shelf registration
9 Nov 23
424B3
Prospectus supplement
15 Dec 22
S-3
Shelf registration
1 Dec 22
S-3
Shelf registration
30 Oct 20
424B5
Prospectus supplement for primary offering
30 Oct 20
424B5
Prospectus supplement for primary offering
1 May 20
424B5
Prospectus supplement for primary offering
29 Apr 20
S-8
Registration of securities for employees
26 Jun 19
424B3
Prospectus supplement
20 Apr 18
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
2 May 22
DEF 14A
Definitive proxy
25 May 21
DEF 14A
Definitive proxy
11 May 20
DEF 14A
Definitive proxy
16 May 19
DEF 14A
Definitive proxy
10 May 18
DEF 14A
Definitive proxy
24 May 17
DEF 14A
Definitive proxy
12 May 16
DEF 14A
Definitive proxy
5 May 15
DEF 14A
Definitive proxy
6 May 14
Other
EFFECT
Notice of effectiveness
18 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
UPLOAD
Letter from SEC
28 Nov 23
EFFECT
Notice of effectiveness
13 Dec 22
CORRESP
Correspondence with SEC
8 Dec 22
UPLOAD
Letter from SEC
7 Dec 22
EFFECT
Notice of effectiveness
12 Nov 20
UPLOAD
Letter from SEC
6 Nov 20
CORRESP
Correspondence with SEC
6 Nov 20
EFFECT
Notice of effectiveness
19 Apr 18
Ownership
4
CHRIS A RALLIS
27 Mar 24
4
Robert Andrade
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
4
Robert Andrade
25 Mar 24
144
Notice of proposed sale of securities
25 Mar 24
SC 13G
Solas Capital Management, LLC
14 Feb 24
4
Robert Andrade
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
4 Jan 24
4
Rosty Raykov
29 Dec 23